Filteren op Last updated date SelectNaVoorFrom - To Date Einddatum Deze week Deze maand Afgelopen week Afgelopen maand Category HumanCorporateVeterinaryHerbal Topic MedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceClinical trialsAdvanced therapiesData on medicinesCompliance and inspectionsInnovationMedicine shortagesResearch and developmentBiosimilarsSMEAntimicrobial resistanceCorporateGovernanceBrexitQuality of medicinesGeneric and hybrid medicinesEarly accessMedicines for use outside the EUFeesProduct informationScientific adviceMedical devicesMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate usePRIMECareersMedication errorParallel distributionProcurement Diseases area Viral diseasesCancerImmune-system diseasesDiabetesNeurodegenerative diseasesCardiovascular diseasesHIV and AIDS Responsible body CHMP CVMP PRAC Management Board COMP PDCO CMDh HMPC CAT Patient safety information Patient safety Laat dit veld leeg Filter Resultaten (3841) Sort by Last update date (new to old)Last update date (old to new)A-ZZ-A Laat dit veld leeg Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021 26 maart 2021NewsHumanCOVID-19Generic and hybrid medicinesMedicinesReferrals EMA issues advice on use of regdanvimab for treating COVID-19 26 maart 2021NewsHumanCOVID-19Medicines COVID-19 Vaccine AstraZeneca – Update on ongoing evaluation of blood clot cases 25 maart 2021NewsHumanCOVID-19Vaccines EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials 22 maart 2021NewsHumanCOVID-19Medicines Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 16-18 March 2021 19 maart 2021NewsVeterinaryMedicines COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets 19 maart 2021NewsHumanCOVID-19Vaccines Investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events continues 16 maart 2021NewsHumanCOVID-19Vaccines EMA’s safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events – further update 15 maart 2021NewsHumanCOVID-19Vaccines EMA Management Board – highlights of March 2021 meeting 12 maart 2021NewsCorporate Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 March 2021 12 maart 2021NewsHumanCOVID-19PharmacovigilanceReferrals 1 … 69 70 71 72 73 Page 73 of 385 74 75 76 77 … 385
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021 26 maart 2021NewsHumanCOVID-19Generic and hybrid medicinesMedicinesReferrals
EMA issues advice on use of regdanvimab for treating COVID-19 26 maart 2021NewsHumanCOVID-19Medicines
COVID-19 Vaccine AstraZeneca – Update on ongoing evaluation of blood clot cases 25 maart 2021NewsHumanCOVID-19Vaccines
EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials 22 maart 2021NewsHumanCOVID-19Medicines
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 16-18 March 2021 19 maart 2021NewsVeterinaryMedicines
COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets 19 maart 2021NewsHumanCOVID-19Vaccines
Investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events continues 16 maart 2021NewsHumanCOVID-19Vaccines
EMA’s safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events – further update 15 maart 2021NewsHumanCOVID-19Vaccines
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 March 2021 12 maart 2021NewsHumanCOVID-19PharmacovigilanceReferrals